Repros Therapeutics Inc. (NASDAQ: RPRX) shares rose 5.6% to $10.24. Repros Therapeutics initiated two Phase 2B uterine fibroid studies. The company is expecting dossier to be filed by end of first quarter. Share volume was 20,000, compared to an all-day average of 249,000
